Chesterfield, MO, United States of America

Julie Dyall

This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Apath, LLC. Active years: 2004.

USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 4.0

ph-index = 1


Company Filing History:


Years Active: 2004

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Julie Dyall: Innovator in Antiviral Research

Introduction

Julie Dyall is a prominent inventor based in Chesterfield, MO (US). She has made significant contributions to the field of antiviral research, particularly through her innovative patent that focuses on viral replicon culture systems. Her work is essential in the ongoing battle against viral infections.

Latest Patents

Julie Dyall holds a patent for "Multiple viral replicon culture systems." This patent provides methods and compositions for screening candidate antiviral agents using cells that contain subgenomic viral replication systems, such as replicons and minigenomes. The methods involve the simultaneous assay of more than one subgenomic viral replication system, which enhances the efficiency of antiviral research. Compositions useful for these methods are also included in her patent.

Career Highlights

Julie Dyall is associated with Apath, LLC, where she applies her expertise in antiviral research. Her work at Apath has positioned her as a key player in the development of innovative solutions for viral infections.

Collaborations

Throughout her career, Julie has collaborated with notable colleagues, including Charles P Romano and Paul D Olivo. These collaborations have further enriched her research and contributed to advancements in the field.

Conclusion

Julie Dyall's contributions to antiviral research through her innovative patent and work at Apath, LLC highlight her importance in the scientific community. Her dedication to developing effective antiviral agents is paving the way for future advancements in healthcare.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…